Fumaria parviflora

Fumaria parviflora Lam. — A Comprehensive Reference

1. Identity, Taxonomy, and Natural Source

Accepted botanical name: Fumaria parviflora Lam. (Lamarck, 1786). Fumaria parviflora carries the widely recognized synonym Fumaria indica, and the two names are used interchangeably throughout the scientific literature. It is an important medicinal herb widely known in the Ayurvedic and Unani systems of medicine.

Family: The medicinal plant Fumaria parviflora Lam. is a member of the Fumarioideae / Fumariaceae (bleeding-heart) family. Some botanical authorities place the genus within the broader family Papaveraceae.

Morphology and habitat: Fumaria parviflora, commonly known as fine-leaf fumitory or Indian fumitory, is a delicate, pale green, annual herb. It is an annual weed that grows in a variety of environments, including cultivated fields, plains, and low hills across Europe, Asia, and Africa. Its habitat spans the Indo-Gangetic plain, the lower Himalaya, and the Nilghiri Mountains, where it grows as a weed of cultivation. Fumaria parviflora is a small branched annual herb found in many parts of the world, including Saudi Arabia and Pakistan. The colors of the flowers of Fumaria parviflora are white.

Common names across languages and traditions: It is commonly known as "Pitpapra" in India and as "Shahtra papra" in Pakistan. In Persian tradition it is known as "Shahtareh" or "Shahatra." In Sanskrit the plant is called Parpat; vernacular names include Pitpapada (Hindi/Deccan), Ban-sulpha (Bengali), Pittapapado (Gujarati), Shahatara/Shatra (Persian/Sindhi), and Tura (Tamil), among others. In the Unani tradition it is referred to as "Shahatra" or "Shaahtaraa," and in Urdu as "Parpata."

Common preparations and dosage forms encountered in commerce and research: The plant is prepared and used in several forms, including aqueous decoctions, aqueous-methanolic extracts, alcoholic (ethanolic) extracts, distillate (aragh or hydrosol), topical creams, capsules, and as a component in polyherbal Ayurvedic and Unani formulations. An aqua distillate of aerial parts of Fumaria parviflora (Aragh-e-Shatareh) is used very frequently in different parts of Iran as a Persian folk medicine. The whole aerial plant is the primary part used medicinally. The whole plant is ascribed to possess medicinal virtues in Ayurvedic and Unani systems of medicine and is also used in preparation of important Ayurvedic medicinal preparations and polyherbal liver formulations.

2. Traditional and Historical Use

Ayurvedic Tradition (India)

Fumaria indica (i.e., F. parviflora) is one of the most commonly used herbs in Ayurvedic, Unani, and other traditional medicine systems in South Asia. It is commonly known as "Pitpapra" in India. Its medicinal values are often mentioned in classical Ayurvedic texts like Charak Samhita, Dhanvantari Nighantu, and Bhava Prakash. In the Sushruta and Charaka tradition, the plant is suggested for fever treatment and disorders related to blood. In Sushruta, the plant is also advised for urinary disorders and chronic skin conditions.

Fumaria parviflora is widely known in the Ayurvedic system of medicine for its diuretic, laxative, anthelmintic, antimicrobial, stomachic, and blood purifier properties.

Unani Tradition (Persia, Arabia, Indian Subcontinent)

Fumaria parviflora has a long history of use in Ayurvedic and Unani systems of medicine. In Iranian traditional medicine (known as Persian Traditional Medicine, or PTM), the plant — called "Shahtareh" — holds an established place. Fumaria parviflora (Aragh-e-Shatareh) is used very frequently in different parts of Iran as a Persian folk medicine. The aerial parts of the plant have been considered to be diuretic, hepatoprotective, laxative, and blood purifier and used in liquid form for treatment of scabies, eczema, acne, and other skin disorders.

In the context of Persian Traditional Medicine formulations, Fumaria parviflora is included in compound preparations such as rhubarb oxymel, which is made from a combination of 24 herbs. Each herb in such preparations is described with specific therapeutic properties — deoppilant (opening or unblocking), tonic (strengthening), and purgative (expellant) effects. TPM texts detail the preparation, benefits, and actions of these herbs, which support liver and digestive health. The most common effect attributed to the herbs in such compounds is their liver obstruction deoppilant property.

Broader Ethnobotanical Use

Several Fumaria species, including F. parviflora, are well-known ethnomedicines in South and West Asia and Europe. Previous ethnobotanical studies showed that they are used in a similar manner, including as anthelmintic, antidyspeptic, blood purifier, cholagogue, diaphoretic, diuretic, laxative, stomachic, sedative, and tonic.

Fumaria has been known since antiquity and was traditionally used by expressing and evaporating the plant's juice. It has a long history of use as a blood purifier in traditional medicine, including the Ayurvedic system, and has been investigated for its therapeutic potential in the management of cardiovascular and hepatobiliary disorders, psoriasis, eczema, and other dermatologic conditions, as well as a laxative and diuretic.

One major ethnomedicinal use of Fumaria species is purifying blood in liver obstruction.

3. Key Constituents and Phytochemistry

Overview of Chemical Classes

The preliminary phytochemical analysis of Fumaria parviflora revealed the presence of flavonoids, glycosides, tannins, saponins, steroids, triterpenoids, phenols, alkaloids, and anthraquinones. Phytochemical studies on Fumaria species revealed the presence of numerous alkaloids, flavonoids, saponins, and terpenoids.

Isoquinoline Alkaloids (Primary Bioactive Class)

Phthalideisoquinolines (PTIs), protoberberines, and spirobenzylisoquinolines (SBIs) are the major alkaloids in the genus Fumaria. The plants biosynthesize a diverse group of biologically active isoquinoline alkaloids, and these may help to explain the use of various Fumaria species in folk medicine.

The principal unique chemical constituents in Fumaria are SBI and PTI alkaloids. SBIs are found almost exclusively in the genera Fumaria and Corydalis. PTIs are the largest group of alkaloids in Fumaria species, playing an essential role in the structural diversity.

Specific alkaloids identified in F. parviflora by chromatographic methods (GC-MS and HPLC) include a large and structurally diverse set. The isoquinoline alkaloids protopine, cryptopine, sinactine, stylopine, bicuculline, adlumine, parfumine, fumariline, fumarophycine, fumaritine, dihydrofumariline, parfumidine, and dihydrosanguinarine have been determined and identified by gas chromatography–mass spectrometry in, among other species, F. parviflora. In a comparative HPLC-DAD study, the richest species in isoquinoline alkaloids among four Fumaria species was F. parviflora.

Additional alkaloids isolated from F. parviflora include parviflorine, a glycosidic spirobenzylisoquinoline. Parviflorine corresponds to (+)-parfumine-β-D-glucoside and upon acid hydrolysis yields (+)-parfumine and D-glucose. Fumariflorine ethyl ester has also been isolated from F. parviflora. The true alkaloid is most probably fumariflorine, which may be considered the first representative of a new group of isoquinoline alkaloids — the O-(β-dimethylaminoethyl)benzoic acids — which originate from the breakdown of phthalideisoquinolines.

Phytochemical study has indicated the presence of alkaloids including coptisine, fumaritine, fumaramine, fumariline, protopine, parfumine, cryptopine, paprafumicin, paprarine, papracinine, fuyuziphine, narlumidine, narceimine, papraline, fumarophycine, and narlumicine; steroids campesterol, β-sitosterol, and stigmasterol; and organic acids fumaric acid and caffeic acid.

Organic Acids

Organic acids — namely citric, coumaric, ferulic, fumaric, malic, 3-hydroxybenzoic, protocatechuic, and caffeic acid (and its methyl ester) — have been identified in Fumaria species by gas chromatography–mass spectrometry. Fumaric acid is one of the most efficacious components of F. parviflora. Moreover, the plant contains fumaric acid esters (FAEs) in addition to monomethylfumarate (MMF), the most bioactive metabolite of FAEs.

Novel Isolated Compound

Structure elucidation by spectral data analysis from a methanolic extract of F. parviflora revealed a novel compound, n-octacosan-7β-ol, with a yield of 0.471%, having significant antimicrobial activity against Leishmania donovani promastigotes, Staphylococcus epidermidis, Escherichia coli, Candida albicans, and Aspergillus niger in vitro.

Phenolic Constituents

The aqueous extract of F. parviflora leaves mainly contains flavonoids (flavonols and quercetin), whereas the ethanolic extract possesses alkaloids (like fumariline, dihydrofumariline, fumaritine, and oxyberberine) and phenols (vanillic acid and cis- and trans-isomers of ferulic acid).

4. Established and Proposed Mechanisms of Action

Protopine — The Central Isoquinoline Alkaloid

The biological activity of Fumaria species is generally associated with the presence of isoquinoline alkaloids, the most essential of which is protopine. This alkaloid has strong anti-hepatotoxic action; it inhibits histamine H1-receptors and platelet aggregation; it inhibits the serotonin transporter and the noradrenaline transporter and has demonstrated antidepressant, antimicrobial, antiviral, and anti-inflammatory action. It was also reported that protopine ingestion down-regulated glutamine levels in rat brain by activation of glutamate dehydrogenase and could assist fortification against transient cerebral ischemic injury.

Fumaric Acid Esters and Immunomodulation

F. parviflora contains fumaric acid esters (FAEs) in addition to monomethylfumarate (MMF), the most bioactive metabolite of FAEs. FAEs have anti-inflammatory effects; they can block the proinflammatory actions of human C-reactive protein (CRP). Some studies showed that MMF can increase IL-4, an anti-inflammatory interleukin, or can decrease IFN-γ, an inflammatory factor, producing a reduction in inflammatory responses. The antioxidant, anti-inflammatory, and neuroprotective effects of fumarates are regulated via activation of NRF2 (nuclear factor erythroid 2-related factor 2) and HCAR2 and by control of immunometabolism.

Smooth Muscle / Gastrointestinal Mechanisms

Experiments using isolated gastrointestinal tract tissue have demonstrated both antispasmodic and prokinetic activities of Fumaria extracts. Cholinergic, muscarinic, and calcium channel involvement has also been demonstrated, with a concentration-response relationship described.

Anticholinesterase Activity

Acetylcholinesterase inhibitory activity of 10 Fumaria species, including F. parviflora, was measured by a modified spectrophotometric method developed by Ellman. All of the extracts displayed high inhibitory activity, ranging between 84.98 ± 1.07% and 96.89 ± 0.17%. The results were compared to galanthamine as the reference compound.

Neurological/Anxiolytic Properties

Fumitory may have diverse effects on the nervous system, including potential anxiolytic and procognitive effects that have been attributed to protopine and other psychoactive alkaloids in the herb, with some postulating that fumitory may be a functionally novel type of anxiolytic through the inhibition of cytokine expression in the nervous system. These findings are based on preclinical and in silico data and have not been confirmed in human trials.

5. Scientific Evidence by Area of Use

5.1 Dermatology — Chronic Hand Eczema

Evidence level: One randomized, double-blind, placebo-controlled clinical trial (moderate quality for a single small study).

A randomized, double-blind, placebo-controlled clinical trial was conducted by Jowkar et al. (Shiraz University of Medical Sciences, Iran, 2011). Fumaria parviflora, known as Shahtareh in Persian, is a folk medicine for eczema. The study aimed to evaluate the effect of alcoholic extract of Fumaria parviflora on hand eczema. In the study, 44 patients with hand eczema were randomly assigned to apply a 4% cream of Fumaria parviflora or vehicle cream to the hand twice daily for 4 weeks. The reduction of eczema area and severity index (EASI) score before and two weeks after therapy was statistically significant between vehicle-treated and treated groups. Only one patient showed side effects such as erythema. The authors concluded that Fumaria parviflora appears to be tolerated by most patients and its extract may be considered as an effective agent for treatment of chronic hand eczema.

The purported mechanism in the context of eczema relates to its content of fumaric acid esters. FP contains fumaric acid esters (FAEs) in addition to monomethylfumarate (MMF), the most bioactive metabolite of FAEs. FAEs have anti-inflammatory effects; they can block the proinflammatory actions of human C-reactive protein (CRP). This single small trial requires confirmation in larger, independent studies before definitive conclusions can be drawn.

5.2 Dermatology / Nephrology — Uremic Pruritus in Hemodialysis Patients

Evidence level: One randomized, double-blind, placebo-controlled clinical trial.

Uremic pruritus (UP) is a common, bothersome symptom in hemodialysis patients with end-stage renal disease. The immunohypothesis is currently favored as an explanation of the cause of UP. Fumaria parviflora is a medicinal herb with several pharmacological properties, including prominent anti-inflammatory activity. A study aimed to assess the efficacy of FP for reducing UP severity among HD patients. A total of 79 HD patients with pruritus were randomly assigned to receive either FP or a placebo for eight weeks. The serum IFN-γ concentration significantly decreased in the Fumaria parviflora group (P < 0.001), and the serum IL-4 concentration significantly increased in the Fumaria parviflora group (P = 0.028). The dosage used in the registered protocol for this type of trial was 2 capsules three times a day before mealtimes for 8 weeks. In the FP group, four patients experienced gastric pain that led to two patients dropping out of the study. One patient complained of small rashes on both legs and feet, but this did not lead to drug discontinuation.

5.3 Oncology-Adjacent — Hot Flashes in Breast Cancer Survivors

Evidence level: Mentioned in a randomized controlled trial evaluating the combination of chicory and fumitory.

F. parviflora has been tested clinically for hot flashes among breast cancer survivors. The two herbs (fumitory and chicory) were well tolerated in these clinical trials, and there were no serious adverse events. This remains an area of early investigation; the existing evidence is limited and involves F. parviflora as part of a combination preparation rather than in isolation.

5.4 Hepatoprotection

Evidence level: Preclinical (animal and in vitro) only; no published human trials identified.

The hepatoprotective activity of an aqueous-methanolic extract of Fumaria parviflora was investigated against paracetamol- and CCl4-induced hepatic damage. Paracetamol (1 g/kg orally) produced 100% mortality in mice; pretreatment of animals with the plant extract (500 mg/kg orally) reduced the death rate to 50%. Pretreatment of rats with plant extract (500 mg/kg, orally twice daily for 2 days) prevented (P < 0.001) the paracetamol-induced rise in serum enzymes alkaline phosphatase (ALP) and transaminases (GOT and GPT), whereas the same dose of the extract was unable to prevent (P > 0.05) the CCl4-induced rise in serum enzyme levels. F. asepalae, F. densiflora, F. indica, F. officinalis, F. parviflora, and F. vaillantii are critically examined for their ethnomedicinal uses in hepatoprotection. The hepatoprotective evidence remains confined to animal models, and human clinical data are lacking.

5.5 Antidiabetic / Hypoglycemic Activity

Evidence level: Preclinical (animal models) with one reported clinical study on diabetes (cited but not yet fully published as a standalone paper); overall evidence preliminary.

Fumaria parviflora Lam. has been used in traditional medicine in the treatment of several diseases such as diabetes. A study was designed to evaluate the hypoglycaemic effects of methanolic extract (ME) of F. parviflora in normal and streptozotocin-induced diabetic rats. Diabetes mellitus was induced by intraperitoneal single injection of streptozotocin (55 mg/kg). Diabetic animals were additionally treated with ME (150 mg/kg/day and 250 mg/kg/day, i.p. respectively) for seven consecutive days. The findings indicated that F. parviflora has significant hypoglycemic effect on STZ-induced diabetic rats with no effects on blood glucose levels of normal rats.

A separate animal study examining the interaction with diabetes-related liver disease used the following protocol: The aim of that study was to investigate the effects of Fumaria parviflora as an herbal source and glibenclamide as a chemical drug on the liver tissue of diabetic rats. Male Wistar rats (n=32) were classified into four groups (8/group), including control, diabetic (induced by 50 mg/kg streptozotocin), 250 mg/kg hydroalcoholic extract of Fumaria parviflora, and 5 mg/kg glibenclamide groups. After 21 days of treatment, liver tissues and blood samples were stored to test lipid profile, liver enzymes, and some oxidative stress markers. Three clinical studies have been compiled in recent reviews; these include a study based on treatment of diabetes. However, that clinical diabetic study has not been independently retrieved and detailed in full-text form by current searches, so its results cannot be described with full specificity here.

5.6 Gastrointestinal — Prokinetic and Laxative Effects

Evidence level: Preclinical (in vivo animal and isolated tissue studies); IBS clinical data exist for the genus but are limited.

A study was designed to provide pharmacological basis for the medicinal use of Fumaria parviflora in gut motility disorders. The in-vivo prokinetic and laxative assays were conducted in mice. Isolated intestinal preparations (ileum and jejunum) from different animal species (mouse, guinea-pig, and rabbit) were separately suspended in tissue baths. The spasmogenic responses were recorded using isotonic transducers. The aqueous-methanol extract of Fumaria parviflora, which tested positive for the presence of alkaloids, saponins, tannins, and anthraquinones, showed partially atropine-sensitive prokinetic and laxative activities in vivo in mice at 30 and 100 mg/kg.

A randomized, placebo-controlled, blind clinical study found a decrease in irritable bowel syndrome (IBS)–associated pain with Fumaria; however, there was no difference over placebo using the global assessment measures of IBS. This suggests the evidence for GI effects remains mixed at the clinical level.

5.7 Anti-inflammatory Activity

Evidence level: Preclinical (animal models and in vitro); clinical signals observed in the uremic pruritus trial.

A study was conducted for evaluation of the anti-inflammatory activity of leaves of F. parviflora and the underlying mechanisms using in vivo acute and sub-acute models of inflammation. Two extracts (aqueous and ethanolic) that were selected for the study contain different phytochemical constituents which have free radical scavenging activity that may have a possible role in countering the inflammatory response. The mechanism proposed includes suppression of pro-inflammatory cytokines (TNF-α, IL-1, IL-6), which was evaluated in these animal models. Clinical modulation of IFN-γ and IL-4 was subsequently observed in the uremic pruritus trial described above.

5.8 Antimicrobial Activity

Evidence level: In vitro only.

The in vitro antileishmanial evaluation of a novel isolated compound (n-octacosan-7β-ol) against Leishmania donovani promastigotes was investigated by growth kinetics assay. Disc diffusion and broth micro-dilution methods were used to study the antibacterial and antifungal potential. Structure elucidation revealed the compound had significant antimicrobial activity against Leishmania donovani promastigotes, Staphylococcus epidermidis, Escherichia coli, Candida albicans, and Aspergillus niger in vitro, with GI50 = 5.35 and MIC values of 250 μg/ml. The isolated compound did not show adverse effects against mammalian macrophages. All antimicrobial evidence is limited to in vitro studies and has not been confirmed in human subjects.

5.9 Anticancer Activity

Evidence level: In vitro and in silico; no clinical human trials identified.

Protopine and QBA alkaloids found in Fumaria species have been studied for their antitumor activity. Chemical constituents of F. parviflora have been reported to demonstrate various pharmacological activities including anticancer activity. Though it is widely studied using several in vitro and in vivo models and tested clinically for skin diseases, several gaps and research priorities have been identified that need to be addressed in the future, such as active ingredients and their mechanism of action in applications including immunomodulation and hepatic diseases.

6. Body Systems and Health Areas Associated with F. parviflora

• Hepatobiliary system: One major ethnomedicinal use of Fumaria species is purifying blood in liver obstruction. Multiple animal studies have examined hepatoprotective effects.
• Gastrointestinal system: Ethnobotanical uses include antidyspeptic, laxative, stomachic, cholagogue, and antidiarrheal roles.
• Dermatological / integumentary system: Traditional use for eczema, scabies, acne, and other skin disorders, supported by one RCT.
• Renal / nephrological system: Use as a diuretic in traditional medicine; clinical trial data for uremic pruritus in hemodialysis patients.
• Immune system: FAEs have anti-inflammatory effects, capable of blocking the proinflammatory actions of human C-reactive protein (CRP).
• Endocrine / metabolic system: Antidiabetic and hypoglycemic activity documented in preclinical models.
• Nervous system: Potential anxiolytic and procognitive effects attributed to protopine and other alkaloids, including inhibition of cytokine expression in the nervous system. These are preclinical hypotheses only.
• Reproductive system: Pharmacological studies have shown F. parviflora to possess reproductive effects, though this area requires further investigation.
• Cardiovascular system: Protopine inhibits histamine H1-receptors and platelet aggregation, providing mechanistic rationale for cardiovascular-related traditional uses.

7. Dosage Forms and Doses Reported in Studies

The following dosages are reported as stated in identified sources. No standardized or regulatory-approved dosing exists for this plant.

• Topical cream — chronic hand eczema (human RCT): A 4% cream of Fumaria parviflora or vehicle cream applied to the hand twice daily for 4 weeks.
• Oral capsules — uremic pruritus (clinical trial protocol): 2 capsules three times a day before mealtimes for 8 weeks.
• Animal study — hepatoprotective (aqueous-methanolic extract): 500 mg/kg orally in mice and rats (pretreatment doses), administered twice daily for 2 days.
• Animal study — prokinetic/laxative (aqueous-methanolic extract, mice): 30 and 100 mg/kg in vivo in mice.
• Animal study — hypoglycemic (methanolic extract, i.p.): 150 mg/kg/day and 250 mg/kg/day (i.p.) for seven consecutive days post streptozotocin induction.
• Animal study — antidiabetic and hepatoprotective (hydroalcoholic extract): 250 mg/kg hydroalcoholic extract of F. parviflora administered over 21 days, with endpoints measuring lipid profile, liver enzymes, and oxidative stress markers.

8. Safety Considerations and Notable Adverse Effects

Tolerability in Clinical Trials

Clinical studies have evaluated the effects of F. parviflora extract on chronic hand eczema and uremic pruritus in hemodialysis patients. The two herbs were well tolerated in these clinical trials, and there were no serious adverse events.

In the chronic hand eczema trial, only one patient showed side effects such as erythema.

In the uremic pruritus trial, four patients in the FP group experienced gastric pain that led to two patients dropping out. One patient complained of small rashes on both legs and feet. In the placebo group, abdominal cramps in one patient and constipation in another patient led to two patients dropping out. Gastric irritation thus represents the most consistently reported adverse effect in human clinical use.

Preclinical Toxicology

Toxicological studies of several Fumaria species have been conducted, and most of these investigations showed that these folk medicines exhibited no adverse effects.

At 500 mg/kg orally in mice, the plant extract caused significant prolongation in pentobarbital-induced sleep as well as increased strychnine-induced lethality, suggestive of central nervous system effects. This CNS interaction signal from preclinical work has not been characterized in humans.

Knowledge Gaps

Although there are many papers describing the bioactivity of crude extracts of Fumaria species, few purified constituents have been studied in detail for their mechanism of action and safety. Though the plant is widely studied using several in vitro and in vivo models and tested clinically for skin diseases, several gaps and research priorities have been identified that need to be addressed in the future, such as active ingredients and their mechanism of action, and applications in immunomodulation and hepatic diseases.

Evidence Base — Overall Characterization

A 2025 review compiled 26 studies evaluated for pharmacological properties of F. parviflora. Most of these studies were based on animal models. Three clinical studies were compiled. The overall body of human clinical evidence is therefore small — three published trials covering dermatological and renal pruritus endpoints — with the bulk of the pharmacological evidence deriving from in vitro and animal experiments. The available clinical trials are limited by small sample sizes and, in some cases, combination-product designs. Independent replication of all clinical findings is required before firm conclusions about efficacy can be drawn.

References

• Sharma A. et al. From roots to remedies: Exploration of medicinal potential of Fumaria parviflora Lam. in drug discovery. ScienceDirect, 2025.
• Jowkar F. et al. The Effects of Fumaria parviflora L Extract on Chronic Hand Eczema: A Randomized Double-Blind Placebo Controlled Clinical Trial. Iran Red Crescent Med J. 2011;13(11):824–828. PMC3371888.
• Jowkar F. et al. The effects of Fumaria parviflora L extract on chronic hand eczema: a randomized double-blind placebo controlled clinical trial. PubMed PMID: 22737422.
• Kumar M. et al. A review on ethnobotany, phytochemistry and pharmacology of Fumaria indica (Fumitory). PMC3609363.
• A review on ethnobotany, phytochemistry and pharmacology of Fumaria indica (Fumitory). Asian Pacific Journal of Tropical Biomedicine, 2012.
• Fumaria — ScienceDirect Topics overview (citing Diverse alkaloids and biological activities of Fumaria, Papaveraceae).
• Diverse alkaloids and biological activities of Fumaria (Papaveraceae): An ethnomedicinal group. Fitoterapia, 2020.
• Anti-inflammatory effect of Fumaria parviflora leaves based on TNF-α, IL-1, IL-6 and antioxidant potential. PMC5329175.
• New phytoconstituents from the aerial parts of Fumaria parviflora Lam. PMC4065466.
• Central composite design expert-supported development and validation of HPTLC method: Relevance in quantitative evaluation of protopine in Fumaria indica. PMC7132833.
• Isolation, characterization and antimicrobial evaluation of a novel compound N-octacosan 7β ol, from Fumaria parviflora Lam. PMC3995687.
• Najeeb-ur-Rehman et al. Species and tissue-specificity of prokinetic, laxative and spasmodic effects of Fumaria parviflora. BMC Complement Altern Med. 2012;12:16.
• Selective protective effect of an extract from Fumaria parviflora on paracetamol-induced hepatotoxicity. PubMed PMID: 8909978.
• Hypoglycemic Activity of Fumaria parviflora in Streptozotocin-Induced Diabetic Rats. PubMed PMID: 24312837.
• Akrami R. et al. Effects of Fumaria parviflora L on Uremic Pruritus in Hemodialysis Patients: A Randomized, Double-Blind, Placebo-Controlled Trial. Jundishapur J Nat Pharm Prod. 2017;12(3).
• Al-Snafi AE. Fumaria parviflora — A Review. IAJPS 2018;05(03):1728–1738.
• New Alkaloids From Fumaria parviflora. ResearchGate.
• Direct determination of alkaloid contents in Fumaria species by GC-MS. PubMed PMID: 12494757.
• Alkaloids and organic acids content of eight Fumaria species. Academia.edu.
• Emerging Therapeutic Applications for Fumarates. Trends in Pharmacological Sciences, 2021.
• Khosropanah A. et al. Effects of Chicory and Fumitory on Hot Flashes Among Breast Cancer Survivors: A Randomized, Double-Blind Placebo-Controlled Trial. J Integr Complement Med. 2023.
• IRCT: Comparison of Fumaria parviflora L. with placebo on treatment of refractive uremic pruritus of hemodialysis patients. Iranian Registry of Clinical Trials.
• Fumaria parviflora, Lamk — Indian Medicinal Plants (Wisdomlib/Hooker Flora of British India).
• Fumaria Uses, Benefits & Dosage — Drugs.com Natural Products Database.
• Western and complementary alternative medicine treatment of uremic pruritus: A literature review. PMC8532575.
• Shahatra (F. parviflora Lam.) — A comprehensive review of its ethnopharmacology, phytochemistry and pharmacology. ResearchGate, 2021.